Trading Halt: AusCann Group Holdings Ltd (ASX: AC8) stock was placed in a trading halt at the request of the company on July 03, 2018 and it will resume normal trading from 5th July, 2018 or when the announcement is released to the market. It is indicated that the company might be intending to raise funds. On the other hand, AC8 has planned to accelerate its Australian medical cannabis manufacturing operation with the appointment of Luke Pigeau as master grower. The company has signed a cultivation research agreement with Canadian group, Jade Cannabis for an initial three-year period to develop and optimise the AusCann cannabis cultivation system. Moreover, AC8 and Tasmanian Alkaloids (TasAlk) has signed an exclusive strategic partnership to jointly establish the cultivation, manufacturing, and distribution operations for cannabinoid pharmaceuticals in Australia and overseas. Further, the company has completed design of the Australian facility and state of the art cultivation rooms and has ordered monitoring systems from Canada. Meanwhile, AC8 stock has fallen 17.95% in three months as on July 02, 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.